09 Aug Capsida Biotherapeutics
Peter Anastasiou, CEO and Board Member
Oct. 8 | 3:45pm | FLW Ballroom G
Thousand Oaks, California
(Private)
Capsida Biotherapeutics is a fully integrated gene therapy company with a central nervous system (CNS) pipeline consisting of disease modifying and potentially curative treatments for rare and more common diseases across all ages. Capsida’s systemically delivered gene therapies utilize proprietary engineered capsids that enable high transduction levels to desired tissues and cells, while limiting tropism to non-target organs, such as the liver. Capsida has three wholly owned programs, including potential best-in-class treatments for genetic epilepsy due to STXBP1 mutations and Parkinson’s disease associated with GBA mutations (PD-GBA), both of which are in IND-enabling studies. In addition to its wholly owned programs, the Company has CNS partnerships with AbbVie, Lilly, CRISPR Therapeutics, and the AbbVie partnership was expanded to include ophthalmology disorders. Capsida was founded in 2019 by Versant Ventures and Westlake Village BioPartners and originated from the laboratory of Viviana Gradinaru, Ph.D., a neuroscience professor at Caltech.
